AKT1 and diffuse large B-cell lymphoma: Despite evidence supporting both SRC kinases and AKT as therapeutic targets in DLBCL [37, 38, 39, 40], the clinical activity of dasatinib and of the AKT inhibitor MK‐2206 as single agents has been limited [41].